Schema therapy versus cognitive behavioral therapy versus individual supportive therapy for depression in an inpatient and day clinic setting: study protocol of the OPTIMA-RCT.
Cognitive behavioral therapy
Depression
Mechanisms of change
Personalized psychiatry
Psychotherapy
Randomized controlled trial
Relapse prevention
Schema therapy
Supportive therapy
Treatment prediction
Journal
BMC psychiatry
ISSN: 1471-244X
Titre abrégé: BMC Psychiatry
Pays: England
ID NLM: 100968559
Informations de publication
Date de publication:
14 10 2020
14 10 2020
Historique:
received:
27
05
2020
accepted:
19
09
2020
entrez:
15
10
2020
pubmed:
16
10
2020
medline:
11
2
2021
Statut:
epublish
Résumé
Major depressive disorder represents (MDD) a major cause of disability and disease burden. Beside antidepressant medication, psychotherapy is a key approach of treatment. Schema therapy has been shown to be effective in the treatment of psychiatric disorders, especially personality disorders, in a variety of settings and patient groups. Nevertheless, there is no evidence on its effectiveness for MDD in an inpatient nor day clinic setting and little is known about the factors that drive treatment response in such a target group. In the current protocol, we outline OPTIMA (OPtimized Treatment Identification at the MAx Planck Institute): a single-center randomized controlled trial of schema therapy as a treatment approach for MDD in an inpatient and day clinic setting. Over the course of 7 weeks, we compare schema therapy with cognitive behavioral therapy and individual supportive therapy, conducted in individual and group sessions and with no restrictions regarding concurrent antidepressant medication, thus approximating real-life treatment conditions. N = 300 depressed patients are included. All study therapists undergo a specific training and supervision and therapy adherence is assessed. Primary outcome is depressive symptom severity as self-assessment (Beck Depression Inventory-II) and secondary outcomes are clinical ratings of MDD (Montgomery-Asberg Depression Rating Scale), recovery rates after 7 weeks according to the Munich-Composite International Diagnostic Interview, general psychopathology (Brief Symptom Inventory), global functioning (World Health Organization Disability Assessment Schedule), and clinical parameters such as dropout rates. Further parameters on a behavioral, cognitive, psychophysiological, and biological level are measured before, during and after treatment and in 2 follow-up assessments after 6 and 24 months after end of treatment. To our knowledge, the OPTIMA-Trial is the first to investigate the effectiveness of schema therapy as a treatment approach of MDD, to investigate mechanisms of change, and explore predictors of treatment response in an inpatient and day clinic setting by using such a wide range of parameters. Insights from OPTIMA will allow more integrative approaches of psychotherapy of MDD. Especially, the identification of intervention-specific markers of treatment response can improve evidence-based clinical decision for individualizing treatment. Identifier on clinicaltrials.gov : NCT03287362 ; September, 12, 2017.
Sections du résumé
BACKGROUND
Major depressive disorder represents (MDD) a major cause of disability and disease burden. Beside antidepressant medication, psychotherapy is a key approach of treatment. Schema therapy has been shown to be effective in the treatment of psychiatric disorders, especially personality disorders, in a variety of settings and patient groups. Nevertheless, there is no evidence on its effectiveness for MDD in an inpatient nor day clinic setting and little is known about the factors that drive treatment response in such a target group.
METHODS
In the current protocol, we outline OPTIMA (OPtimized Treatment Identification at the MAx Planck Institute): a single-center randomized controlled trial of schema therapy as a treatment approach for MDD in an inpatient and day clinic setting. Over the course of 7 weeks, we compare schema therapy with cognitive behavioral therapy and individual supportive therapy, conducted in individual and group sessions and with no restrictions regarding concurrent antidepressant medication, thus approximating real-life treatment conditions. N = 300 depressed patients are included. All study therapists undergo a specific training and supervision and therapy adherence is assessed. Primary outcome is depressive symptom severity as self-assessment (Beck Depression Inventory-II) and secondary outcomes are clinical ratings of MDD (Montgomery-Asberg Depression Rating Scale), recovery rates after 7 weeks according to the Munich-Composite International Diagnostic Interview, general psychopathology (Brief Symptom Inventory), global functioning (World Health Organization Disability Assessment Schedule), and clinical parameters such as dropout rates. Further parameters on a behavioral, cognitive, psychophysiological, and biological level are measured before, during and after treatment and in 2 follow-up assessments after 6 and 24 months after end of treatment.
DISCUSSION
To our knowledge, the OPTIMA-Trial is the first to investigate the effectiveness of schema therapy as a treatment approach of MDD, to investigate mechanisms of change, and explore predictors of treatment response in an inpatient and day clinic setting by using such a wide range of parameters. Insights from OPTIMA will allow more integrative approaches of psychotherapy of MDD. Especially, the identification of intervention-specific markers of treatment response can improve evidence-based clinical decision for individualizing treatment.
TRIAL REGISTRATION
Identifier on clinicaltrials.gov : NCT03287362 ; September, 12, 2017.
Identifiants
pubmed: 33054737
doi: 10.1186/s12888-020-02880-x
pii: 10.1186/s12888-020-02880-x
pmc: PMC7557007
doi:
Banques de données
ClinicalTrials.gov
['NCT03287362']
Types de publication
Clinical Trial Protocol
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
506Subventions
Organisme : Max Planck Institute of Psychiatry
ID : n.a.
Références
Psychol Med. 2015 Nov;45(15):3269-79
pubmed: 26165748
J Psychiatr Res. 2005 Jan;39(1):1-9
pubmed: 15504418
Psychol Med. 2011 Jun;41(6):1165-74
pubmed: 20932356
J Psychosom Res. 1967 Aug;11(2):213-8
pubmed: 6059863
J Behav Ther Exp Psychiatry. 2014 Sep;45(3):319-29
pubmed: 24650608
Z Psychosom Med Psychother. 2007;53(2):111-28
pubmed: 17688782
J Abnorm Psychol. 2015 Aug;124(3):532-48
pubmed: 26052618
J Affect Disord. 2011 Sep;133(1-2):137-49
pubmed: 21555156
Epidemiol Psychiatr Sci. 2017 Feb;26(1):22-36
pubmed: 26810628
Mol Psychiatry. 2020 Jul;25(7):1430-1446
pubmed: 31969693
Annu Rev Clin Psychol. 2007;3:1-27
pubmed: 17716046
Community Ment Health J. 1968 Dec;4(6):443-53
pubmed: 24185570
JAMA Psychiatry. 2017 Mar 1;74(3):233-242
pubmed: 28146251
J Pers Disord. 2014 Aug;28(4):518-40
pubmed: 24511899
Nervenarzt. 2015 May;86(5):542-8
pubmed: 25877043
Clin Psychol Psychother. 2016 Mar-Apr;23(2):107-17
pubmed: 25425509
J Clin Psychol. 2006 Apr;62(4):445-58
pubmed: 16470629
J Behav Ther Exp Psychiatry. 2016 Jun;51:66-73
pubmed: 26780673
Psychother Res. 2020 Feb;30(2):137-150
pubmed: 30632922
Psychotherapy (Chic). 2016 Dec;53(4):402-412
pubmed: 27177079
Depress Anxiety. 2013 Jul;30(7):624-30
pubmed: 23288666
Int J Psychophysiol. 2015 Nov;98(2 Pt 2):338-350
pubmed: 26272488
BMJ. 2010 Mar 23;340:c332
pubmed: 20332509
J Clin Med. 2019 Apr 05;8(4):
pubmed: 30959828
J Consult Clin Psychol. 2014 Apr;82(2):202-11
pubmed: 24491077
Clin Psychol Rev. 2016 Dec;50:95-107
pubmed: 27770716
J Consult Clin Psychol. 2005 Feb;73(1):78-85
pubmed: 15709834
JAMA. 2004 Jun 2;291(21):2581-90
pubmed: 15173149
Nat Neurosci. 2015 Apr;18(4):590-6
pubmed: 25730669
Ann Intern Med. 2008 Nov 18;149(10):734-50
pubmed: 19017592
Psychiatry Res. 2016 Jun 30;240:421-430
pubmed: 27155594
Acta Psychiatr Scand. 2019 May;139(5):404-419
pubmed: 30834514
J Consult Psychol. 1967 Apr;31(2):109-18
pubmed: 5342732
Neurosci Biobehav Rev. 2018 Dec;95:61-72
pubmed: 30278195
Am J Psychiatry. 2014 Mar;171(3):305-22
pubmed: 24322378
J Cogn Neurosci. 2010 Dec;22(12):2702-15
pubmed: 19929761
Psychol Assess. 2018 Sep;30(9):1199-1213
pubmed: 29672073
Neuropsychiatr Dis Treat. 2019 May 10;15:1249-1258
pubmed: 31190831
J Pers Soc Psychol. 1988 Jun;54(6):1063-70
pubmed: 3397865
J Affect Disord. 2013 Feb 15;145(1):21-8
pubmed: 22868056
J Consult Clin Psychol. 2000 Aug;68(4):603-14
pubmed: 10965636
Annu Rev Clin Psychol. 2019 May 7;15:207-231
pubmed: 30550721
Behav Res Ther. 2009 Nov;47(11):938-45
pubmed: 19691953
Front Hum Neurosci. 2014 Nov 19;8:825
pubmed: 25477800
Psychol Methods. 2010 Sep;15(3):209-33
pubmed: 20822249
Annu Rev Clin Psychol. 2018 May 7;14:209-236
pubmed: 29494258
PLoS One. 2020 Jan 2;15(1):e0227364
pubmed: 31895938
BMC Psychiatry. 2020 May 11;20(1):213
pubmed: 32393358
Nat Genet. 2018 May;50(5):668-681
pubmed: 29700475
Assessment. 2013 Jun;20(3):370-83
pubmed: 23612961
J Health Soc Behav. 1983 Dec;24(4):385-96
pubmed: 6668417
Psychiatry Res. 2016 Jun 30;240:412-420
pubmed: 27149410
Br J Psychiatry. 2004 May;184:386-92
pubmed: 15123501
Clin Psychol Rev. 2015 Jul;39:30-41
pubmed: 25932958
Behav Res Ther. 2015 Nov;74:60-71
pubmed: 26432172
Clin Psychol Rev. 2013 Apr;33(3):426-47
pubmed: 23422036
Front Psychol. 2017 Nov 24;8:2053
pubmed: 29225589
Psychiatr Clin North Am. 2008 Sep;31(3):405-20, vi
pubmed: 18638643
Am J Public Health. 1996 May;86(5):726-8
pubmed: 8629727
Am J Psychiatry. 2015 Feb 1;172(2):124-38
pubmed: 25640931
Front Psychol. 2016 Sep 14;7:1373
pubmed: 27683567
World Psychiatry. 2013 Jun;12(2):137-48
pubmed: 23737423
Lancet. 2018 Nov 10;392(10159):1789-1858
pubmed: 30496104
Contemp Clin Trials Commun. 2017 Jan 06;5:80-85
pubmed: 29740624
Aust N Z J Psychiatry. 2018 Sep;52(9):887-897
pubmed: 29325436
Br J Psychiatry. 1979 Apr;134:382-9
pubmed: 444788
J Couns Psychol. 2018 Jan;65(1):51-64
pubmed: 29355344
Psychol Med. 2019 Jan;49(2):200-211
pubmed: 30134999
Lancet. 2018 Apr 7;391(10128):1357-1366
pubmed: 29477251
Depress Anxiety. 2013 Jun;30(6):515-27
pubmed: 23468126
PLoS One. 2014 Jan 08;9(1):e83875
pubmed: 24416178
Psychiatry Res. 2017 Jul;253:9-12
pubmed: 28319789
Psychol Assess. 2017 Oct;29(10):1302-1308
pubmed: 28240933
Braz J Psychiatry. 2017 Jan-Mar;39(1):12-20
pubmed: 27901214
Sleep. 2007 Apr;30(4):519-29
pubmed: 17520797
BMC Psychiatry. 2011 Aug 17;11:134
pubmed: 21849054
Annu Rev Public Health. 2013;34:119-38
pubmed: 23514317
Depress Anxiety. 1999;10(4):142-6
pubmed: 10690575
J Affect Disord. 2011 Nov;134(1-3):20-31
pubmed: 21163534
Transl Psychiatry. 2020 May 29;10(1):172
pubmed: 32472038
JAMA Psychiatry. 2018 Apr 1;75(4):336-346
pubmed: 29450462
Eur Neuropsychopharmacol. 2014 Jan;24(1):5-50
pubmed: 24176673
Biol Psychiatry. 2010 Jun 1;67(11):1067-74
pubmed: 20138254
J Consult Clin Psychol. 2007 Jun;75(3):475-88
pubmed: 17563164
J Behav Ther Exp Psychiatry. 2018 Mar;58:97-105
pubmed: 29035800
J Behav Ther Exp Psychiatry. 2016 Sep;52:59-67
pubmed: 27016846
BMJ. 2009 Jun 29;338:b2393
pubmed: 19564179
BMC Psychiatry. 2016 May 23;16:159
pubmed: 27216151
CNS Drugs. 2015 Jul;29(7):577-89
pubmed: 26290264
Eur Arch Psychiatry Clin Neurosci. 2018 Apr;268(3):215-217
pubmed: 29546658
Front Psychol. 2016 Dec 22;7:1987
pubmed: 28066304
World Psychiatry. 2016 Oct;15(3):245-258
pubmed: 27717254
Psychother Res. 2020 Jul;30(6):763-775
pubmed: 31507250
J Behav Ther Exp Psychiatry. 2005 Sep;36(3):254-64
pubmed: 15978543
Psychol Sci Public Interest. 2002 Nov;3(2):39-77
pubmed: 26151569
Neurobiol Learn Mem. 2011 Nov;96(4):553-63
pubmed: 21704176
Am J Psychother. 1971 Jul;25(3):350-61
pubmed: 4936109
J Pers Assess. 2012;94(4):418-26
pubmed: 22439655
Psychother Psychosom. 2018;87(5):276-284
pubmed: 30007961
PLoS One. 2018 Feb 13;13(2):e0192761
pubmed: 29438435
Psychother Res. 2020 Jun;30(5):591-603
pubmed: 32400306
Front Psychol. 2016 Jun 14;7:862
pubmed: 27378968
Front Genet. 2018 Jul 17;9:257
pubmed: 30065751
J Affect Disord. 2015 Feb 1;172:96-102
pubmed: 25451401
J Affect Disord. 2001 May;64(2-3):203-16
pubmed: 11313087
Psychother Res. 2009 Jul;19(4-5):418-28
pubmed: 19034715
Arch Gen Psychiatry. 2006 Jun;63(6):649-58
pubmed: 16754838
J Behav Ther Exp Psychiatry. 2010 Mar;41(1):52-9
pubmed: 19896642
Contemp Clin Trials Commun. 2019 Jan 24;14:100330
pubmed: 30775612
Behav Ther. 2016 Nov;47(6):966-980
pubmed: 27993344
Annu Rev Psychol. 2011;62:583-619
pubmed: 19575624
World J Biol Psychiatry. 2010 Mar;11(2 Pt 2):165-80
pubmed: 19670087
J Affect Disord. 2008 Jul;109(1-2):1-20
pubmed: 18082896
J Affect Disord. 2013 Nov;151(2):500-5
pubmed: 23870427
Annu Rev Clin Psychol. 2018 May 7;14:91-118
pubmed: 29401044
J Biom Biostat. 2017 Feb 24;8(1):1-8
pubmed: 30555734
BMJ. 2011 Oct 18;343:d5928
pubmed: 22008217
Soc Psychiatry Psychiatr Epidemiol. 1998 Nov;33(11):568-78
pubmed: 9803825
PLoS One. 2016 Mar 02;11(3):e0149530
pubmed: 26934499
Aging Ment Health. 2018 Jun;22(6):738-747
pubmed: 28429623
Front Psychol. 2015 Jan 22;5:1592
pubmed: 25657631
Dialogues Clin Neurosci. 2019 Dec;21(4):397-405
pubmed: 31949407
PLoS Med. 2013;10(5):e1001454
pubmed: 23723742
Biol Psychiatry. 2020 Jan 15;87(2):185-193
pubmed: 31856957
BMC Public Health. 2012 Jan 24;12:75
pubmed: 22272740
Trials. 2016 Oct 8;17(1):487
pubmed: 27717405
J Behav Ther Exp Psychiatry. 2014 Jun;45(2):242-51
pubmed: 24342235
J Pers Soc Psychol. 2003 Aug;85(2):348-62
pubmed: 12916575
J Affect Disord. 2017 Mar 01;210:72-81
pubmed: 28013125
Clin Psychol Psychother. 2014 Jan-Feb;21(1):29-38
pubmed: 22933391
Br J Psychiatry. 2014 Feb;204(2):144-50
pubmed: 24311553
J Pers Disord. 2014 Aug;28(4):577-93
pubmed: 24256103
J Behav Ther Exp Psychiatry. 2009 Jun;40(2):317-28
pubmed: 19176222
J Affect Disord. 2019 Jan 15;243:503-515
pubmed: 30286415
Psychother Res. 2013;23(1):105-16
pubmed: 23194587
Cognit Ther Res. 2018;42(6):782-793
pubmed: 30416229
Br J Clin Psychol. 1984 May;23 ( Pt 2):93-9
pubmed: 6722384
Int J Cogn Ther. 2014 Jan 9;7(3):255-271
pubmed: 26401194
Int J Mol Sci. 2020 Feb 01;21(3):
pubmed: 32024055
Mol Psychiatry. 2018 Feb;23(2):335-343
pubmed: 27752078
Clin Psychol Psychother. 2010 May-Jun;17(3):165-82
pubmed: 20486158
BMC Med. 2020 Jun 5;18(1):170
pubmed: 32498707
J Couns Psychol. 2019 Jul;66(4):508-517
pubmed: 31144846
Front Psychol. 2016 Nov 25;7:1851
pubmed: 27933020
BMC Med Res Methodol. 2011 Feb 21;11:21
pubmed: 21338524
Psychol Bull. 2013 Jan;139(1):81-132
pubmed: 22642228
Annu Rev Clin Psychol. 2008;4:1-32
pubmed: 18509902
J Clin Psychiatry. 2008 Aug;69(8):1287-92
pubmed: 18605812
World J Biol Psychiatry. 2017 Feb;18(1):5-28
pubmed: 27603714
Biol Psychiatry. 2020 Jul 15;88(2):169-184
pubmed: 31926635
J Affect Disord. 2008 Nov;111(1):40-5
pubmed: 18358539
Am J Psychiatry. 2010 Dec;167(12):1445-55
pubmed: 20843873